The FDA has proposed removing phenylephrine, a common ingredient in decongestants, due to its ineffectiveness, which may ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

So far, there have been no U.S.-approved treatments for the condition, and doctors often treat patients with a variety of ...

Innocan has received FDA support to advance its LPT-CBD platform for human use under the 505(b)(2) abbreviated pathway, ...

The Canadian “Certificate ... an aim to encouraging new drugs a quick introduction into Canada. Thus, companies interested in ...

Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, today announced the U.S. Food and Drug Administration (FDA) has approved MI Cancer Seektm for ...

Targets the reduction in CABG-related bleeding severity due to the blood thinning drug, ticagrelor – a major unmet medical need in heart attack ...

Drugs with a ... reported to either the FDA or Health Canada, depending on location. IQVIA’s Multinational Integrated Data Analysis (MIDAS) data were used for this study, which includes 89% of US drug ...

Kubapharm.com was issued a warning letter by the FDA on March 30, 2022 for selling drugs without requiring a prescription and lacking DEA registration on the website. The screenshot taken October ...

Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors — making it the first antitissue-factor pathway inhibitor to be allowed for ...

Sulopenem, which will now go by the commercial moniker Orlynvah, was approved by the FDA Friday to treat uncomplicated urinary tract infections (uUTIs) caused by E. coli, Klebsiella pneumoniae or ...

(RTTNews) - Iterum Therapeutics plc (ITRM) Friday announced that the U.S. Food and Drug Administration (FDA) has approved Iterum's new drug application for Orlynvah (sulopenem etzadroxil and ...